BC Extra | Oct 11, 2019
Company News

Management tracks: Chan leaving FDA’s China office; plus Galera, Aridis and Palladio

Irene Chan has stepped down as deputy director of FDA's China office. She joined the office in 2009 as one of its first policy analysts, covering food safety. As deputy director, she worked closely with...
BC Innovations | Mar 7, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Engineered viruses A method for enhancing viral sensitivity to host IFN could be used to generate highly immunogenic, live virus-based vaccines against infection. The approach involves using saturation mutagenesis and next-generation sequencing to compare...
BC Innovations | Feb 28, 2018
Translation in Brief

Interferon non-interference

Researchers from UCLA have developed a method to enhance the immunogenicity of live virus-based vaccines by inactivating the virus’ ability to evade interferon-mediated host immunity. Having shown proof-of-concept for an influenza A vaccine, the team...
BC Week In Review | Feb 23, 2018
Clinical News

CDC panel recommends AZ's FluMist for 2018-19 season

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 12-2 in favor of recommending FluMist Quadrivalent from AstraZeneca plc (LSE:AZN; NYSE:AZN) as an age-appropriate option for flu prevention for the 2018-2019 influenza season, according to...
BC Extra | Feb 21, 2018
Company News

CDC panel recommends AZ's FluMist for 2018-19 season

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 12-2 in favor of recommending FluMist Quadrivalent from AstraZeneca plc (LSE:AZN; NYSE:AZN) as an age-appropriate option for flu prevention for the 2018-2019 influenza season, according to...
BC Week In Review | Jul 18, 2016
Clinical News

FluMist Quadrivalent regulatory update

FDA said the benefits of FluMist Quadrivalent from AstraZeneca to prevent seasonal influenza continue to outweigh the risks. The announcement follows the recommendation last month by the U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)...
BC Week In Review | Jun 27, 2016
Clinical News

FluMist Quadrivalent regulatory update

The U.S. CDC’s Advisory Committee on Immunization Practices (ACIP) recommended against the use of FluMist Quadrivalent from AstraZeneca to prevent seasonal influenza during the 2016-17 flu season. The intranasal live attenuated influenza vaccine (LAIV) is...
BC Extra | Jun 24, 2016
Company News

CDC panel snubs AZ's FluMist

CDC's Advisory Committee on Immunization Practices (ACIP) recommended against use of FluMist from AstraZeneca plc (LSE:AZN; NYSE:AZN) to prevent seasonal influenza during the 2016-17 flu season. The intranasal live attenuated influenza vaccine (LAIV) is the...
BC Week In Review | Sep 28, 2015
Company News

Daiichi Sankyo, AstraZeneca deal

AstraZeneca’s MedImmune LLC unit granted Daiichi Sankyo exclusive rights to develop and commercialize FluMist Quadrivalent in Japan. AZ will receive an upfront fee and is eligible for development and sales milestones. AZ will supply FluMist...
BC Week In Review | Jun 30, 2014
Clinical News

Fluenz Tetra regulatory update

The U.S. Centers for Disease Control and Prevention 's Advisory Committee on Immunization Practices (ACIP) recommended use of FluMist Quadrivalent from AstraZeneca to prevent seasonal influenza in healthy children ages 2-8 years who have no...
Items per page:
1 - 10 of 367